Current concepts and review of pimecrolimus in the treatment of psoriasis

Dermatologic Clinics

Volumn 22, Issue 4, 2004, Pages 461-465

  Wolff, Klaus ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HEADACHE; HEART RATE VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; NAUSEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; REVIEW; STEADY STATE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAXIMUM TOLERATED DOSE; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RATS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 4344625851     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2004.03.013     Document Type: Review

References (22)

1. Meingassner J.G., Grassberger M., Fahrngruber H., Moore H.D., Schuuman H., Stuetz A. A novel anti-inflammory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 137:1997;568-576
2. Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 141:1999;264-273
3. Neckermann G., Bavandi A., Meingassner J.G. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol. 142:2000;669-679
4. Paul C., Graeber M., Stuetz A. Ascomycins, promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs. 9:2000;69-77
5. Wellington K., Spencer C.M. Adis new drug profile: ASM 981. BioDrugs. 74:2000;409-416
6. Stuetz A., Grassberger M., Meingassner J.G. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 20:2001;233-241
7. Rappersberger K., Meingassner J.G., Fialla R., Foedinger D., Sterniczky B., Rauch S., et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 106:1996;701-710
8. Van Leent E.J.M., Gräber M., Thurston M., Wagenaar A., Spuls P.I., Bos J. Effectiveness of the ascomycin macrolactam SDZ in the topical treatment of atopic dermatitis. Arch Dermatol. 134:1998;805-809
9. Harper J., Green A., Scott G., Gruendl E., Dorobek B., Cardno M., et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 144:2001;781-789
10. Queille-Roussel C., Graeber M., Thurston M., Lachapelle J.M., Decroix J., DeCuyper C., et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 42:2000;149-150
11. Mrowietz U., Gräber M., Brautigam M., Thurston M., Wagenaar A., Weidinger G., et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol. 139:1998;992-996
12. Van Leent E.J.M., Ebelin M.E., Burtin P., Spuls P.I., Bos J.D. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions. Eur Acad Dermatol Venereol. 11:1998;S133-S134
13. Rappersberger K., Komar M., Ebelin M.E., Scott G., Burtin P., Creig G., et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 119:2002;876-887
14. Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 141:1999;264-273
15. Kalthoff F.S., Chung J., Grassberger M., Stuetz A. SDZ ASM 981 potently inhibits the induction of coreceptors involved in the accessory cell-dependent activation of inflammation-mediating T cells [abstract]. J Invest Dermatol. 117:2001;440
16. Hultsch T., Müller K.D., Meingassner J.G., Grassberger M., Schopf R.E., Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res. 290:1998;501-507
17. Zuberbier T., Chong S.U., Grunow K., Guhl S., Welker P., Grassberger M., et al. The ascomycin macrolactam pimecrolimus (Elideland®, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 108:2001;275-280
18. Meingassner J.G., Fahrngruber H., Barandi A. SDZ ASM 981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis [abstract]. J Invest Dermatol. 114:2000;832
19. Meingassner J.G., Hiestand P., Bigaud M., Grassberger M., Schuurman H., Tanner M., et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506. J Invest Dermatol. 117:2001;532
20. Griffiths C., Dubertret L., Gottlieb A. Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect [abstract]. J Invest Dermatol. 121:2003;301
21. Wolff K., Caro I., Murrell D., Ortonne J.P. Safety profile of oral pimecrolimus in atopic eczema and psoriasis: a pooled analysis from two dose-finding studies [abstract]. J Invest Dermatol. 121:2003;1245
22. Hanifin J., Fleming C., Korman N., Reitamo S. Treatment with oral pimecrolimus significantly improves atopic dermatitis (AD) with a clear dose-response effect [abstract]. J Invest Dermatol. 121:2003;1240